Ramelteon (melatonin receptor agonist) for neuromuscular degenerative disease and neuroimmunological disease;examination for safety.

Trial Profile

Ramelteon (melatonin receptor agonist) for neuromuscular degenerative disease and neuroimmunological disease;examination for safety.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2011

At a glance

  • Drugs Ramelteon (Primary)
  • Indications Autoimmune diseases of the nervous system; Neurodegenerative disorders; Neuromuscular disorders
  • Focus Pharmacodynamics
  • Most Recent Events

    • 11 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top